Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms, Plasma Cell 3Myasthenia Gravis 3Neoplasms 2Lymphoma 2Leukemia 2Infections 2Neuromyelitis Optica 1Myelitis, Transverse 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Limbic Encephalitis 1Immunoglobulin Light-chain Amyloidosis 1Epilepsy 1Epilepsies, Partial 1Drug Resistant Epilepsy 1Autoimmune Diseases of the Nervous System 1Autoimmune Diseases 1

Interventions

telitacicept 2Prednisone 2Blood Specimen Collection 2thymoglobulin 1remdesivir 1prednylidene 1fludarabine 1deltacortene 1carmustine, poliferprosan 20 drug combination 1apremilast 1Vitamin D 1Valsartan 1Telemedicine 1Surveys and Questionnaires 1Standard of Care 1Specimen Handling 1Pyridostigmine Bromide 1Practice Guidelines as Topic 1Population Groups 1Peripheral Blood Stem Cell Transplantation 1Nivolumab 1Mycophenolic Acid 1Music Therapy 1Methods 1Melphalan 1Mastectomy, Segmental 1Mammaplasty 1Interviews as Topic 1Infliximab 1Immunotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Autoimmune Diseases × Immunoglobulins, Intravenous × Clear all
NCT01545518 2014-09-01

IVIG Treatment for Refractory Immune-Related Adult Epilepsy

Emory University

Phase 2 Terminated
20 enrolled 3 charts

Drug Resistant Epilepsy, Autoimmune Diseases, Epilepsy, Epilepsies, Partial, Autoimmune Diseases of the Nervous System, Limbic Encephalitis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡